4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists

Core Insights - 4D Molecular Therapeutics is a late-stage biotechnology company focused on developing durable and disease-targeted therapeutics that aim to transform treatment paradigms and provide significant benefits to patients [3]. Presentation Details - The company will present interim results from the SPECTRA Phase 2a clinical trial evaluating intravitreal 4D-150 in adults with diabetic macular edema on July 31, 2025 [2]. - The presentation will include a 52-week primary endpoint analysis and a 60-week analysis, with all patients having reached 60 weeks as of the data cutoff date of May 2, 2025 [2]. - Additionally, results from the PRISM Phase 2b clinical trial evaluating intravitreal 4D-150 in adults with neovascular age-related macular degeneration will be presented on August 1, 2025 [2]. Product Candidates - The lead product candidate, 4D-150, is designed to provide multi-year sustained delivery of anti-VEGF therapies through a single intravitreal injection, significantly reducing the treatment burden associated with current bolus injections [3]. - 4D-150 is currently in Phase 3 development for wet age-related macular degeneration and is also being studied for diabetic macular edema [3]. - The second product candidate, 4D-710, is the first known genetic medicine to successfully deliver and express the CFTR transgene in the lungs of cystic fibrosis patients after aerosol delivery [3].